receptor antagonist/inverse agonist (Ki
= 141 nM) with greater than 70-fold selectivity over CB2
> 10 μ
M). Structurally dissimilar from SR 141716A and AM 251. Shows weak binding to both 5-HT2
= 6.4 μ
M) and muscarinic receptors (Ki
= 2.1 μ
Soluble to 30 mM in DMSO
Store at RT
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
Felder et al.
Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle.
Holland et al.
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
Life Sci., 2005;76:1307
The citations listed below are publications that use Tocris products. Selected citations for LY 320135 include:
Showing Results 1 - 4 of 4